L Xerri

821 total citations
27 papers, 474 citations indexed

About

L Xerri is a scholar working on Molecular Medicine, Pharmacology and Applied Microbiology and Biotechnology. According to data from OpenAlex, L Xerri has authored 27 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Medicine, 14 papers in Pharmacology and 7 papers in Applied Microbiology and Biotechnology. Recurrent topics in L Xerri's work include Antibiotic Resistance in Bacteria (16 papers), Antibiotics Pharmacokinetics and Efficacy (13 papers) and Antibiotic Use and Resistance (7 papers). L Xerri is often cited by papers focused on Antibiotic Resistance in Bacteria (16 papers), Antibiotics Pharmacokinetics and Efficacy (13 papers) and Antibiotic Use and Resistance (7 papers). L Xerri collaborates with scholars based in Italy, France and United States. L Xerri's co-authors include Daniel C. Pevear, Denis M. Daigle, Robert E. Lee Trout, Christopher J. Burns, Jason Weiss, Enza Di Modugno, Bin Liu, Luc Ferrari, G. Galassi and Randy W. Jackson and has published in prestigious journals such as Analytical Biochemistry, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

L Xerri

25 papers receiving 431 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L Xerri Italy 8 307 205 130 92 68 27 474
Soon-Ee Cheah Australia 9 338 1.1× 266 1.3× 145 1.1× 85 0.9× 56 0.8× 10 475
B Kolek United States 13 294 1.0× 307 1.5× 206 1.6× 151 1.6× 46 0.7× 16 637
Elizabeth Gradelski United States 13 260 0.8× 261 1.3× 129 1.0× 114 1.2× 35 0.5× 19 513
Ziad Tarazi United States 10 310 1.0× 218 1.1× 138 1.1× 83 0.9× 43 0.6× 15 429
Kenji Yamawaki Japan 8 337 1.1× 243 1.2× 82 0.6× 115 1.3× 94 1.4× 12 487
Mototsugu Yamada Japan 7 223 0.7× 165 0.8× 108 0.8× 101 1.1× 83 1.2× 8 362
P. B. Harper United Kingdom 9 247 0.8× 195 1.0× 104 0.8× 81 0.9× 26 0.4× 17 377
MICHAEL J. BASKER United States 12 244 0.8× 274 1.3× 81 0.6× 124 1.3× 117 1.7× 35 503
Neu Hc United States 12 215 0.7× 275 1.3× 135 1.0× 66 0.7× 20 0.3× 41 520
Concepción Segura Spain 10 442 1.4× 269 1.3× 183 1.4× 93 1.0× 17 0.3× 12 556

Countries citing papers authored by L Xerri

Since Specialization
Citations

This map shows the geographic impact of L Xerri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Xerri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Xerri more than expected).

Fields of papers citing papers by L Xerri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Xerri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Xerri. The network helps show where L Xerri may publish in the future.

Co-authorship network of co-authors of L Xerri

This figure shows the co-authorship network connecting the top 25 collaborators of L Xerri. A scholar is included among the top collaborators of L Xerri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Xerri. L Xerri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Géhin, Thomas, Benoît Gilquin, L Xerri, et al.. (2025). Effects of the physico-chemical properties of amino acids and chemically functionalized surfaces on DIOS-MS analysis. Analytical Biochemistry. 700. 115792–115792.
2.
Trout, Robert E. Lee, Allison L. Zulli, Eugen F. Mesaros, et al.. (2021). Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes. Journal of Medicinal Chemistry. 64(14). 10155–10166. 30 indexed citations
3.
4.
5.
Liu, Bin, Robert E. Lee Trout, Guo‐Hua Chu, et al.. (2019). Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. Journal of Medicinal Chemistry. 63(6). 2789–2801. 219 indexed citations
6.
Daigle, Denis M., Natalia Kurepina, Barry N Kreiswirth, et al.. (2018). 1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa. Open Forum Infectious Diseases. 5(suppl_1). S419–S420. 16 indexed citations
7.
Young, Clint, et al.. (2007). P1673 Safety and pharmacokinetics of single-dose intravenous ad-ministration of PZ-601: a novel investigational carbapenem. International Journal of Antimicrobial Agents. 29. S473–S474.
8.
Penault–Llorca, F, et al.. (1997). [Clear cell sarcoma of the kidney relapsing after 10 years of asymptomatic evolution].. PubMed. 17(6). 400–2. 2 indexed citations
9.
Gaviraghi, G., et al.. (1996). Synthesis and antimicrobial evaluation of 2 beta-chloromethyl-6 beta-carbamoylmethyl-penam-1,1-dioxide-3-carboxylic acid.. PubMed. 51(7). 535–8. 1 indexed citations
10.
Modugno, Enza Di, et al.. (1994). In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria. Antimicrobial Agents and Chemotherapy. 38(10). 2362–2368. 89 indexed citations
11.
12.
Sambri, Vittorio, Fabio Rumpianesi, L Xerri, & Roberto Cevenini. (1989). In- VitroActivity of Ofloxacin againstChlamydia trachomatis. Journal of Chemotherapy. 1(4). 231–232. 1 indexed citations
13.
Cuffini, Annamaria, et al.. (1987). Synergy of ceftazidime and human macrophages on phagocytosis and killing of Staphylococcus aureus and Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 20(2). 261–271. 14 indexed citations
14.
Xerri, L, et al.. (1986). Ofloxacin: bactericidal effect in an in vitro pharmacokinetic model.. PubMed. 5(2). 83–7. 1 indexed citations
15.
Xerri, L, et al.. (1984). In vitro evaluation of ceftazidime (GR 20263), amikacin and sisomicin, in a model simulating serum pharmacokinetics of therapeutic doses.. PubMed. 3(5). 271–7. 1 indexed citations
16.
Martini, Alessandro & L Xerri. (1982). Study of diffusion of cefuroxime into middle ear effusions of patients with chronic purulent otitis media. Journal of Antimicrobial Chemotherapy. 10(3). 197–198. 2 indexed citations
17.
Greca, G. La, S Biasioli, S. Chiaramonte, et al.. (1982). Pharmacokinetics of intravenous and intraperitoneal cefuroxime during peritoneal dialysis.. PubMed. 20(2). 92–4. 5 indexed citations
18.
Xerri, L, et al.. (1982). Experimental infections for the evaluation of beta-lactamase resistance. Antimicrobial Agents and Chemotherapy. 21(2). 201–203. 2 indexed citations
19.
Okolicsànyi, Lajos, et al.. (1982). Pharmacokinetic studies of cefuroxime in patients with liver cirrhosis.. PubMed. 32(7). 777–82. 3 indexed citations
20.
Macario, Alberto J.L., et al.. (1975). Lymphocyte Functions in the Rat Spleen at Various Times after Urethan Administration. Tumori Journal. 61(4). 319–326. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Soon-Ee Cheah Breakdown of academic impact, for papers by B Kolek Breakdown of academic impact, for papers by Elizabeth Gradelski Breakdown of academic impact, for papers by Ziad Tarazi Breakdown of academic impact, for papers by Kenji Yamawaki Breakdown of academic impact, for papers by Mototsugu Yamada Breakdown of academic impact, for papers by P. B. Harper Breakdown of academic impact, for papers by MICHAEL J. BASKER Breakdown of academic impact, for papers by Neu Hc Breakdown of academic impact, for papers by Concepción Segura
Rankless by CCL
2026